TECH Stock Price Today (July 2026) — Bio-Techne Corporation Analysis & Key Metrics 2026-07-17
Bio-Techne Corporation (TECH) is trading at $72.12, up 0.49% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $68.00 (-5.7% upside).
- Volatility remains elevated (4.39% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-1.50% YoY) alongside significant competitive pressures.
TECH Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Bio-Techne Corporation - Historical Price & Volume
Market Cap
Enterprise Value: $11.14B
P/E Ratio
Forward P/E: 34.55
Revenue Growth
Year over Year
Analyst Target
+-5.7% upside potential
Key Investor Questions About TECH
What investors need to know before buying
Based on current market data, TECH presents a overbought technical setup with challenging fundamentals.
- Technicals say: Overbought (RSI 81.22)
- Fundamentals say: Challenging (declining revenue trends)
TECH's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for TECH investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $290.32M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, TECH stock traded between $43.20 and $72.16—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 4.39% annualized volatility and β=1.17, the stock exhibits high sensitivity to market moves—making TECH suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bio-Techne (NASDAQ:TECH) and the best and worst performers in the research tools & consumables industry.
SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation
By Karen Roman SkylineDx said the FDA granted Breakthrough Device Designation to Merlin CP-GEP, the company’s gene expression profile test for risk assessment and clinical decision-making in patients with early-stage cutaneous melanoma. The Merlin CP-GEP is the first and only melanoma gene expression profiling test to have this FDA designation and to be included in […] The post SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation appeared first on ExecEdge.
1 Momentum Stock with Impressive Fundamentals and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
The $11 Billion Reason TECH Stock Is Up Today
Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?
Merck KGaA to acquire Bio-Techne in $11.3 billion deal
The deal, Merck's largest since its Sigma-Aldrich buyout, expands its presence in proteins, spatial biology, and cell and gene therapy
Bio-Techne (TECH) Agrees To $11.5 Billion Merck KGaA Buyout
Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has unanimously approved the transaction, which is now subject to regulatory review. The companies highlight expected synergies and accretion to Merck KGaA’s earnings following completion. For investors tracking Bio-Techne, the agreed $11.5b acquisition by Merck KGaA lands after a sharp move in the stock, with NasdaqGS:TECH up 22% over the past week and 47% over the past month. The...
Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal
Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy.
Bio-Techne (TECH) Soars 20% on Merck $11.3B Merger
Bio-Techne Corp. (NASDAQ:TECH) is one of the 9 Stocks Winning by Double Digits. Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors gobbled up shares following news that it is merging with pharmaceutical giant Merck for $11.3 billion. In a statement, Bio-Techne Corp. (NASDAQ:TECH) said […]
Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer
On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.
Frequently Asked Questions
Common investor questions about Bio-Techne Corporation
Bio-Techne Corporation (TECH) is currently trading at $72.12. The RSI (14-day) is at 81.2, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $68.00 implies 5.7% downside from current levels. Volatility is low at 4.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Bio-Techne Corporation (TECH): The trailing P/E ratio is 103.03, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 34.55, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.95, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 5.59. Price-to-Sales is 9.28. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering TECH, the consensus price target is $68.00. This represents a 5.7% downside from the current price of $72.12. The range spans from a low target of $50.00 to a high target of $73.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Bio-Techne Corporation (TECH) pays a dividend with a current yield of approximately 44.00%. The annualized dividend rate is $0.32 per share. The payout ratio is 45.7%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-05-18T00:00:00.000Z.
Key risks for Bio-Techne Corporation (TECH) investors include: 1. Declining revenue (-1.5% YoY), indicating potential business headwinds. 2. Elevated short interest (13.3% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Bio-Techne Corporation's (TECH) current debt and financial health profile: Total debt stands at $290.32M. The debt-to-equity ratio is 13.92, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 4.49, indicating strong short-term liquidity. The quick ratio is 2.80. The company holds $214.11M in cash and equivalents. Free cash flow is positive at $299.85M, providing a cushion for debt servicing and shareholder returns.